Home / Clinical Guideline Hubs / Chapter 10.10
Section 10 — Hematology & Jaundice Verify against local policy v1.0 · July 2026 Baylor Ed. 33 cross-checked Sept 2026

Chapter 10.10 — Vitamin K Deficiency Bleeding (VKDB)

A preventable disease: universal newborn vitamin K prophylaxis, the three timing categories (early/classic/late), and why breastfed infants who miss prophylaxis are at risk of catastrophic intracranial hemorrhage — built on West Midlands Neonatal Guidelines 2025–28 and AAP guidance

Educational guideline — verify locally. Vitamin K prophylaxis route/dose and treatment regimens must follow the Neonatal Formulary and national policy; intramuscular prophylaxis is standard. Does not replace attending judgment.
BEDSIDE ACTION BOX

1. Overview

Overview

Vitamin K deficiency bleeding (formerly hemorrhagic disease of the newborn) results from deficiency of the vitamin-K-dependent clotting factors (II, VII, IX, X). Newborns are naturally vitamin-K-deficient (poor placental transfer, immature gut flora, low breast-milk content), so bleeding is preventable with routine prophylaxis at birth. Where prophylaxis is missed, refused, or given only orally, infants — especially exclusively breastfed ones — remain at risk, and late VKDB can present as fatal or disabling intracranial hemorrhage.

Why This Topic Matters

VKDB is almost entirely preventable with a single injection, yet late VKDB (intracranial hemorrhage in breastfed infants) still occurs when prophylaxis is missed or declined. Universal IM prophylaxis and vigilance for at-risk infants save lives.

2. Who This Guideline Applies To

Scope
  • All newborns (prophylaxis) and infants with suspected/confirmed VKDB or bleeding.
  • Infants with cholestasis/malabsorption or missed/oral-only prophylaxis (higher risk).
  • Cross-references: the bleeding neonate (10.3), cholestasis/prolonged jaundice (10.6), and IVH (9.2).

3. Key Definitions

TermDefinition
VKDBVitamin K deficiency bleeding — bleeding from deficiency of factors II, VII, IX, X.
Vitamin-K-dependent factorsII, VII, IX, X (and proteins C/S) — require vitamin K for activation.
PIVKA-IIMarker of vitamin K deficiency (proteins induced by vitamin K absence).
Prolonged PT/INRHallmark laboratory finding; corrects with vitamin K.

4. Three Categories by Timing

TypeTimingFeatures
Early<24 hoursUsually from maternal drugs interfering with vitamin K (e.g., some anticonvulsants, warfarin, rifampicin); can be severe.
ClassicDay 1–7GI bleeding, bleeding from cord/circumcision/puncture sites, bruising; linked to missed prophylaxis/poor intake.
Late~2–12 weeks (up to 6 months)Often intracranial hemorrhage in an exclusively breastfed infant without IM prophylaxis, or with cholestasis/malabsorption.

5. Risk Factors

Who Is at Risk
  • No prophylaxis, refused prophylaxis, or oral-only prophylaxis (less reliable than IM, especially for late VKDB).
  • Exclusive breastfeeding (low vitamin K content).
  • Cholestasis/malabsorption (e.g., biliary atresia, cystic fibrosis, alpha-1-antitrypsin) — impaired absorption.
  • Maternal medications affecting vitamin K (early VKDB).

6. Prophylaxis (The Key Intervention)

Universal Vitamin K at Birth
  • Offer vitamin K prophylaxis to every newborn; a single intramuscular dose at birth is the most effective and standard route (prevents classic and late VKDB).
  • If parents decline IM, an oral multi-dose regimen may be offered per national policy, but it is less effective for late VKDB and requires completion of all doses — counsel clearly.
  • Infants with cholestasis/malabsorption need ongoing vitamin K supplementation.
  • Verify dose/route against the Neonatal Formulary and national schedule.
Doses, timing and the numbers for counselling (Baylor Ed. 33)
  • Above 1500 g: vitamin K1 (phytonadione) 1 mg IM as a single dose within the first 6 hours. Below 1500 g: 0.3 mg IM as a single dose.
  • Why every infant needs it: factors II, VII, IX and X depend on vitamin K; placental transfer is poor; gut production waits on feeding and colonization; and breast milk is low in vitamin K even when the mother takes supplements — a breastfed infant's intake is only 7–13% of the recommended 10 mcg/day.
  • Higher risk: breastfed infants whose lactation takes days to establish, infants not fed enterally for several days, intestinal malabsorption, and mothers on anticonvulsants — phenytoin especially.
  • Timing categories: early VKDB within 24 hours (almost exclusively after maternal vitamin-K-inhibiting drugs); classic at 2–7 days; late at 1–24 weeks.
  • Without prophylaxis, early and classic VKDB occur in 0.25–1.7% of infants and late VKDB in 4.4–7.2 per 100,000 — and 30–60% of late VKDB includes intracranial haemorrhage. Oral or parenteral vitamin K prevents early disease, but parenteral is best for late disease, and no oral preparation is approved in the United States.
  • When parents decline: it is not legally mandated in Texas, so the conversation carries the weight. Address the common worries directly — it is not a vaccine, contains no mercury and does not cause cancer — and state the risk plainly: an infant who does not receive vitamin K is about 80 times more likely to have a severe bleed, most often in the brain, and natural levels take months to rise. If they still decline, document the discussion in detail and use a refusal-of-treatment form where the institution has one.

7. Presentation

Bleeding + Prolonged PT
  • GI bleeding (haematemesis/melaena), bleeding from cord/puncture/circumcision sites, bruising, and mucosal bleeding.
  • Late VKDB: intracranial hemorrhage (seizures, bulging fontanelle, pallor, encephalopathy) — often the first sign.
  • Laboratory: prolonged PT/INR (and APTT) with a normal platelet count and fibrinogen, correcting with vitamin K — distinguishes VKDB from DIC/other causes (see 10.3).

8. Management Algorithm

1
Prevent
Give IM vitamin K to every newborn; counsel and complete oral regimens if IM declined; supplement in cholestasis.
2
Suspect VKDB
Unexplained bleeding + prolonged PT/INR with normal platelets/fibrinogen, especially with missed/oral prophylaxis or breastfeeding.
3
Treat
Give IV vitamin K; for serious/life-threatening bleeding add clotting-factor replacement (PCC/FFP) per policy; resuscitate.
4
Image if late VKDB
Cranial imaging for suspected intracranial hemorrhage; neurosurgical input as needed.
5
Find the cause
Investigate cholestasis/malabsorption in late VKDB (e.g., biliary atresia); ensure ongoing supplementation and follow-up.
6
⚠ Do-not-miss
Intracranial hemorrhage as the presenting feature; underlying biliary atresia/cholestasis; and confusing VKDB with DIC (platelets/fibrinogen normal in VKDB).

9. Treatment (Verify Doses Locally)

Vitamin K + Factor Replacement for Serious Bleeding
  • Vitamin K intravenously for active bleeding (corrects the coagulopathy over hours).
  • Serious/life-threatening bleeding: add immediate clotting-factor replacement — prothrombin complex concentrate (PCC) or fresh frozen plasma — per policy, alongside resuscitation and blood products for anemia.
  • Treat/refer any intracranial hemorrhage; correct anemia; supportive intensive care.
  • Continue vitamin K and treat the underlying cause (cholestasis/malabsorption).
⚠ Verify

Vitamin K and factor-replacement agents, doses, and routes must follow the Neonatal Formulary and local policy — flagged for expert review.

10. Monitoring

ParameterWhenAction
PT/INR (and APTT)Before/after treatmentConfirm correction with vitamin K.
Platelets/fibrinogenAt diagnosisNormal in VKDB (distinguishes from DIC).
HemoglobinWith bleedingTransfuse for significant anemia.
Cranial imagingSuspected ICHNeurosurgical input.
Cause work-up (cholestasis)Late VKDBInvestigate; ongoing supplementation.

11. Precautions

Safety Cautions
  • Ensure every newborn receives vitamin K prophylaxis — IM is most effective; oral is less reliable for late VKDB and requires all doses.
  • Counsel families who decline IM about the risk of late intracranial hemorrhage.
  • Don't confuse VKDB with DIC — in VKDB platelets and fibrinogen are normal.
  • Investigate cholestasis/malabsorption in late VKDB (e.g., biliary atresia) and supplement ongoing.
  • Give IV vitamin K + factor replacement for serious bleeding; verify doses.

12. Escalation & Family Support

Family-Centered Communication
  • "A vitamin K injection at birth prevents a rare but serious bleeding problem, including bleeding in the brain that can happen weeks later in breastfed babies. We strongly recommend it for every baby."
  • "If you'd prefer not to have the injection, there's an oral course, but it's less reliable and every dose must be completed — we'll explain the risks."

13. Key Pearls

High-Value Clinical Pearls
  • VKDB = deficiency of factors II, VII, IX, X; prolonged PT/INR with normal platelets and fibrinogen, correcting with vitamin K.
  • Three types: early (<24 h, maternal drugs), classic (day 1–7), late (2–12 weeks — intracranial hemorrhage in breastfed infants without IM prophylaxis).
  • IM prophylaxis at birth is the standard and most effective; oral is less reliable for late VKDB.
  • Treat active bleeding with IV vitamin K + factor replacement (PCC/FFP) for serious bleeding.
  • Late VKDB → investigate cholestasis/malabsorption (e.g., biliary atresia).
  • VKDB is not DIC — platelets and fibrinogen are normal.

14. Common Mistakes to Avoid

MistakeWhy it harmsBetter practice
Missing/declined prophylaxis unaddressed.Late VKDB/ICH.Universal IM; counsel if declined.
Assuming oral = IM.Late VKDB risk.Prefer IM; complete oral doses.
Confusing VKDB with DIC.Wrong treatment.Check platelets/fibrinogen (normal in VKDB).
Ignoring cholestasis in late VKDB.Misses biliary atresia.Investigate; supplement.
Vitamin K alone for major bleed.Slow correction.Add factor replacement (PCC/FFP).

15. Board-Style High-Yield Summary

Key Takeaways
  • VKDB = deficiency of vitamin-K-dependent factors (II, VII, IX, X); prolonged PT/INR with normal platelets/fibrinogen, correcting with vitamin K.
  • Types: early (<24 h; maternal drugs), classic (day 1–7), late (2–12 weeks; ICH in breastfed infants without IM prophylaxis or with cholestasis).
  • Prevention: universal vitamin K at birth — IM is standard and most effective; oral is less reliable for late VKDB.
  • Treat active bleeding with IV vitamin K; add factor replacement (PCC/FFP) for serious/life-threatening bleeding.
  • Investigate cholestasis/malabsorption in late VKDB (e.g., biliary atresia).
  • Distinguish from DIC (platelets/fibrinogen normal in VKDB).

16. References

Back to Clinical Guideline Hubs